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The interferon-induced transmembrane (IFITM) pro-
teins have been recently shown to restrict HIV-1
and other viruses. Here, we provide evidence that
IFITM proteins, particularly IFITM2 and IFITM3, spe-
cifically antagonize the HIV-1 envelope glycoprotein
(Env), thereby inhibiting viral infection. IFITMproteins
interact with HIV-1 Env in viral producer cells, leading
to impaired Env processing and virion incorporation.
Notably, the level of IFITM incorporation into HIV-1
virions does not strictly correlate with the extent of
inhibition. Prolonged passage of HIV-1 in IFITM-ex-
pressing T lymphocytes leads to emergence of Env
mutants that overcome IFITM restriction. The ability
of IFITMs to inhibit cell-to-cell infection can be
extended to HIV-1 primary isolates, HIV-2 and SIVs;
however, the extent of inhibition appears to be vi-
rus-strain dependent. Overall, our study uncovers a
mechanism by which IFITM proteins specifically
antagonize HIV-1 Env to restrict HIV-1 infection and
provides insight into the specialized role of IFITMs
in HIV infection.
INTRODUCTION
Interferons are cytokines that inhibit viral infection by inducing
expression of hundreds of the interferon-stimulated genes
(ISGs) (Sadler and Williams, 2008). Among these, APOBEC3G,
TRIM5a, Tetherin or Bst2, SAMHD1, and MxB have been re-
ported as potent anti-HIV restriction factors (Goujon et al.,
2013; Hrecka et al., 2011; Kane et al., 2013; Laguette et al.,
2011; Liu et al., 2013; Neil et al., 2008; Sadler and Williams,
2008; Sheehy et al., 2002; Stremlau et al., 2004; Van Damme
et al., 2008). The interferon-induced transmembrane (IFITM) pro-
teins are recently identified ISGs that have been shown to inhibit
a number of viruses, including influenza A virus (IAV), West NileCvirus, Dengue virus, Marburg virus (MARV), Ebola virus (EBOV),
SARS coronavirus (SARS-CoV), vesicular stomatitis virus
(VSV), and HIV type 1 (HIV-1) (Brass et al., 2009; Chutiwitoonchai
et al., 2013; Huang et al., 2011; Jiang et al., 2010; Li et al., 2013;
Lu et al., 2011; Schoggins et al., 2011; Weidner et al., 2010).
However, the underlying mechanism by which IFITMs broadly
inhibit viral infection is currently not well understood.
One recently recognized mechanism underlying the IFITM-
mediated inhibition of viral infection is inhibition of viral entry,
particularly the Env-mediated virus fusion with target cell mem-
branes (Diamond and Farzan, 2013; Perreira et al., 2013; Smith
et al., 2014).We reported that IFITMs inhibit cell-cell fusionmedi-
ated by all three classes of viral fusion proteins, acting at the level
of hemifusion initiation (Li et al., 2013). Additional studies re-
vealed that IFITM proteins decrease membrane fluidity, possibly
by adopting intramembrane topology and changing curvature (Li
et al., 2013; Lin et al., 2013; Yount et al., 2012). Recent results
using single-viral-particle fusion assays suggest that IFITMs
can also inhibit formation of fusion pores in endosomes (Desai
et al., 2014). The potent inhibitory effect of IFITMs on viral fusion
has been linked to their localization to both endolysosomal com-
partments and plasma membrane, which is determined by post-
translational modification and sorting signals (Chesarino et al.,
2014; Huang et al., 2011; Jia et al., 2012, 2014). Interestingly,
IFITMs have been recently shown to enhance infection of
some viruses, such as human coronavirus HCoV-OC43 (Zhao
et al., 2014). IFITM3 is known to interact with vesicle-mem-
brane-protein-associated protein A (VAPA) and disrupt intracel-
lular cholesterol homeostasis (Amini-Bavil-Olyaee et al., 2013),
but the exact role of cholesterol in IFITM-mediated inhibition of
the viral membrane remains elusive.
We initially reported that inducible expression of IFITMs sup-
presses the replication of HIV-1BH10 strain in SupT1 cells (Lu
et al., 2011). However, other groups did not observe a significant
effect of IFITMs on HIV-1NL43 infection in HeLa-TZM cells (Brass
et al., 2009). Subsequent studies showed that overexpression of
IFITMs can indeed inhibit HIV-1 replication in MT-4 cells (Schog-
gins et al., 2011) and that IFITMs also modestly reduce expres-
sion of some HIV-1 genes, including Gag (Chutiwitoonchaiell Reports 13, 145–156, October 6, 2015 ª2015 The Authors 145
et al., 2013; Ding et al., 2014; Lu et al., 2011). Furthermore, we
recently observed that HIV-1 mutations in env and vpu genes
can promote escape from IFITM1 restriction, and that these mu-
tations appear to correlate with enhanced cell-to-cell transmis-
sion capability of these escape mutants (Ding et al., 2014).
Most recently, Compton, Tartour, and colleagues demonstrated
that IFITMs are incorporated into HIV-1 virions, leading to
impaired viral fusion, infectivity, and spread (Compton et al.,
2014; Tartour et al., 2014). However, the exact mechanism
underlying the IFITM impairment of HIV-1 infection remains
unknown.
Herein, we show that IFITM proteins, especially IFITM2 and
IFITM3, specifically interact with HIV-1 Env in viral producer
cells and antagonize its ability to mediate viral cell-to-cell infec-
tion. In contrast to the study of Compton and Tatour et al.
(Compton et al., 2014; Tartour et al., 2014), we find that IFITM
incorporation into HIV-1 particles does not strictly correlate
with the ability of IFITMs to inhibit cell-to-cell infection. We
confirm our previous finding (Ding et al., 2014) that prolonged
passage of HIV-1 results in the emergence of Env mutations
that overcome the IFITM-mediated restriction of cell-to-cell
infection, resulting in enhanced viral replication. Overall, our
work supports a model by which IFITMs specifically disrupt
the function of HIV-1 Env so as to restrict HIV-1. Results from
this study clarify the molecular mechanisms of IFITM restriction
and provide insight into the specialized role of IFITMs in HIV-1
replication, with possible consequences for HIV-1 transmission
and AIDS pathogenesis.
RESULTS
Expression of IFITM1, 2, and 3 Differentially Inhibits
HIV-1 Infection
Despite the strong inhibition imposed by IFITMs on many envel-
oped viruses, the effect of IFITMs onHIV-1 has been shown to be
comparatively modest (Diamond and Farzan, 2013; Perreira
et al., 2013). Notably, most previous studies are based on cell-
free HIV-1 infection, in which IFITMs are expressed in target
cells. Here, we exploit a highly sensitive intron-Gaussia luciferase
(inGLuc) system developed by David Derse and colleagues (Ma-
zurov et al., 2010) to assess the effect of IFITM expression in
donor cells on HIV-1 single-round cell-to-cell transfer. In this sys-
tem, the Gluc gene can only be expressed upon HIV-1 vector
infection of target cells. We first established Jurkat cell lines sta-
bly expressing IFITM1, IFITM2, or IFITM3 using Jurkat/inGLuc
(a kind gift of Walther Mothes) previously engineered to express
inGLuc HIV-1 vector (Agosto et al., 2014), and we infected these
cells with wild-type (WT) HIV-1NL43 bearing VSV-G so that the
majority of donor cells would be HIV-1 infected. We then cocul-
tured these cells with parental Jurkat cells and measured GLuc
activity 24–48 hr after coculture.
Expression of IFITM proteins, especially IFITM2 and IFITM3,
in donor cells significantly inhibited HIV-1NL43 transmission
from Jurkat/inGLuc to parental Jurkat cells (up to 10-fold) (Fig-
ure 1A). In contrast, IFITM expression in target Jurkat cells
showed very modest effects, i.e., 5%–40% inhibition, on
HIV-1 cell-to-cell transmission (Figure 1A). Similar trends were
also observed when 293T cells served as donor cells and Jurkat146 Cell Reports 13, 145–156, October 6, 2015 ª2015 The Authorsas target cells, although the inhibitory effect of IFITM1 in donor
293T cells was less compared to that in donor Jurkat/inGLuc
cells (Figure 1B), possibly due to the expression of endogenous
IFITMs in Jurkat cells (Lu et al., 2011). We also measured the
infectivity of HIV-1 virions produced from 293T cells in HeLa-
TZM and observed that IFITM2 and IFITM3 significantly dimin-
ished the viral infectivity (Figure 1C). The relatively low inhibitory
effect of IFITM1 on HIV-1 cell-to-cell infection was not due to
different levels of IFITM expression in 293T or Jurkat cells, as
determined by western blotting (Figure 1D). We treated the co-
cultured 293T-Jurkat cells with AMD3100 (a CXCR4 inhibitor),
latrunculin B (LAT-B, an actin polymerization inhibitor), or
VRC01 (a broadly neutralizing antibody against the CD4 binding
site of Env), and we observed that each of these inhibitors mark-
edly reduced cell-to-cell HIV-1 infection (Figure 1E), showing
that HIV-1 transmission from 293T to Jurkat cells is CXCR4 cor-
eceptor and HIV-1 Env dependent and requires a dynamic actin
cytoskeleton.
To directly visualize the effect of IFITMs on HIV-1 cell-to-cell
spread, we performed live-cell imaging by transfecting 293T
cells with an infectious HIV-1 clone that contains an internally in-
serted GFP in Gag (HIV-1NL43-iGFP) along with IFITM expression
vectors. Once again, expression of IFITM2 and IFITM3, but not
IFITM1, in 293T cells significantly inhibited HIV-1NL43-iGFP
spread and syncytium formation from 293T to Jurkat (Figures
1F and S1A). Similar results were also obtained in HIV-1 trans-
mission and cell-cell fusion from 293T to HeLa-TZM cells (Fig-
ure S1B). Collectively, these data demonstrate that expression
of IFITMs in donor cells strongly but differentially inhibits HIV-1
cell-to-cell infection and cell-cell fusion. These findings confirm
the recent reports (Compton et al., 2014; Tartour et al., 2014)
that potent IFITM restriction of HIV-1 infection requires expres-
sion in the producer cell.
Knockdown of Endogenous IFITM Expression in a CD4+
T Cell Line Promotes HIV-1 Cell-to-Cell Infection
CD4+ PM1 T cells express detectable levels of endogenous
IFITM1, IFITM2, and IFITM3 (Lu et al., 2011). We thus tried to
knock down the IFITM expression in PM1 cells by transducing
them with lentiviral small hairpin RNAs (shRNAs) against IFITM1,
2, or 3 and examined the effect on HIV-1 cell-to-cell infection.
The expression level of IFITMs in these PM1 cells was substan-
tially reduced by the shRNA, either in the presence or absence of
interferon treatment (IFNa2b, 500 U), although cross-knock-
down of different human IFITMswas observed (Figure 2A). These
cell lines were infected with HIV-1NL43-iGFP bearing VSV-G for
12 hr, resulting in 97% Gag-iGFP-positive PM1 cells, which
served as donor cells (Figure S2A). After extensive washes, the
PM1 cells were cocultured with target Jurkat cells, which were
pre-labeled with CMTMR (red). The cell-to-cell HIV-1 transmis-
sion efficiency was determined by calculating the GFP+ popula-
tions over time in CMTMR-labeled target Jurkat cells using flow
cytometry.
As shown in Figure 2B, 4 hr after coculture, the HIV-1 Gag-
iGFP transfer from PM1 to Jurkat cells was slightly increased
for PM1 cells expressing shRNA targeting IFITMs compared
to that of cells transduced with scrambled shRNA control.
Notably, the enhancement became apparent at 8 hr in PM1 cells
Figure 1. Expression of IFITMs Differen-
tially Inhibits HIV-1 Cell-to-Cell Infection
(A) Donor Jurkat/inGLuc cells expressing or not
expressing IFITMs were infected with HIV-1NL43
pseudotypes bearing VSV-G and cocultured with
target Jurkat or Jurkat cells stably expressing
IFITMs.
(B)HEK293Tcellswere transiently transfectedwith
HIV-1 NL43/inGLuc plus Env in the presence or
absenceof IFITMsandwere coculturedwith Jurkat
cells stably expressing or not expressing IFITMs.
(C) Effect of IFITMs on cell-free HIV-1 infection.
HIV-1NL43 virions were produced from 293T cells
expressing or not expressing IFITMs, and cell-free
infectivity was determined by infecting HeLa-TZM
cells.
(D) Expressions of IFITM proteins in Jurkat/inGLuc,
Jurkat and 293T cells determined by western
blotting. b-Actin serves as loading control.
(E) Effect of AMD3100 (4 mg/m), LAT-B (1 mg/ml),
and VRC01 (5 mg/ml) on HIV-1 transfer from 293T
to Jurkat cells. All reagents were added immedi-
ately upon coculturing and maintained throughout
the entire assay.
(F) Quantification of HIV-1 transmission/fusion
from 293T to Jurkat/tdTomato cells using live-cell
imaging. HEK293T cells were transfected with
HIV-1NL43 Gag-iGFP and cocultured with Jurkat/
tdTomato cells for 20–24 hr. The numbers of GFP-
and tdTomato-double-positive cells were scored
and plotted relative to that of empty vector
pQCXIP control.
For all figures applicable, the values aremeans and
SDs of three to five independent experiments. *p <
0.05; **p < 0.01; ***p < 0.001. See also Figure S1.expressing shRNA against IFITM2 (23.8%) and IFITM3 (32.8%)
relative to the scrambled shRNA control (13.8%) (Figure 2B).
Azidothymidine (AZT) treatment of cocultured cells at 8 hr
did decrease HIV-1 transmission in IFITM-knockdown PM1
cells compared to untreated cells (Figure 2B), suggesting that
knockdown of IFITMs can enhance productive HIV-1 infection
following cell-to-cell infection (i.e., newly synthesized Gag-
iGFP). The cell-free HIV-1NL43 infection of the mixed PM-1/
Jurkat cell population (without spinoculation) was low
(1.6%), regardless of shRNA IFITM expression. We subse-
quently confirmed the effects of IFITMs knockdown, especially
IFITM3, in primary peripheral blood mononuclear cells (PBMCs),
which served as donor cells for HIV-1 cell-to-cell infection (Fig-
ures 2C–2E). We cannot exclude the possibility that the smaller
effect of IFITM1 and 2 knockdown on viral transmission could
be due to their relatively low knockdown efficiency in PBMCs.
Nonetheless, these results demonstrate that knockdown of
endogenous IFITM expression enhances HIV-1 transmission in
CD4+ T cells.Cell Reports 13, 145–156IFITM Proteins Interact with HIV-1
Env in Viral Producer Cells and
Impair Env Processing and
Incorporation into Virions
One possible mechanism by which IFITM
expression in donor cells could inhibitHIV-1 cell-to-cell infection and infectivity is through association
with HIV-1 Env. As the first step to test this possibility, we per-
formed western blotting to examine HIV-1 Env expression and
processing in 293T cells transiently transfected with HIV-1NL43
in the presence or absence of IFITMs. We found that the ratio
of gp120 or gp41 to gp160 in IFITM-expressing cells, especially
that of IFITM2 and IFITM3, was considerably decreased
compared to that observed in cells transfected with the pQCXIP
vector control (Figures 3A and 3C). These results suggest that
HIV-1 Env processing is impaired by IFITMs. We then carried
out immunoprecipitation (IP) of the cell lysates (containing 1%
NP-40 and 0.1% SDS) with anti-FLAG and observed that
IFITM proteins, especially those expressing IFITM2 and IFITM3,
readily pulled down HIV-1 Env, especially gp41 (Figure 3B, top
and middle panels). IFITM1 was also found to interact with
HIV-1 Env, but with much reduced efficiency (Figure 3B). Impor-
tantly, we did not detect HIV-1 Gag in immunoprecipitated cell
lysates (data not shown), implying that the observed interaction
is HIV-1 Env specific. The interaction between endogenous, October 6, 2015 ª2015 The Authors 147
Figure 2. Knockdown of IFITM Expression
in CD4+ PM1 Cells or PBMCs Promotes
HIV-1 Transmission to Jurkat Cells
(A) Examination of IFITM protein expression in
PM1 cells stably expressing shRNA IFITM1, 2, and
3. Cells were treated with or without 500 U IFNa2b
for 18–24 hr, and lysates were subjected to west-
ern blotting using anti-IFITM1, anti-IFITM2, or
anti-IFITM3 antibodies. Cross-knockdown and
antibody cross-reactions among IFITM1, 2, and 3
are noticed. GAPDH serves as loading control due
to weak signals for b-actin in PM-1 cells.
(B) Summary of flow cytometric analysis of HIV-1
Gag-GFP transfer from PM1 to Jurkat cells. PM-1
cells stably expressing shRNA IFITM1, 2, or 3 or
scramble control were infected with NL43-Gag-
iGFP; cells were cocutured for 4–8 hr with Jurkat
cells that were prelabeledwith CMTMR.Cells were
gated for GFP (Green) and CMTMR (Red) by flow
cytometry (see Figure S2). For 8 hr coculture, cells
were also treated with AZT to ensure that produc-
tiveHIV-1 replication hadoccurred. Datawere from
four independent experiments. All values shown
are normalized against shRNA control either at 4 or
8 hr after coculture, *p < 0.05; **p < 0.01.
(C–E) Knockdown of IFITM expression in PBMCs
enhances HIV-1 cell-to-cell infection. Activated
PBMCs were treated with 500 U IFNa2b and
infected with VSV-G lentiviral pseudotypes en-
coding shRNA IFITM1, 2, or 3 for 48 hr. The
knockdown efficiency was examined by intracel-
lular staining using pooled antibodies against
IFITM1, 2, and 3 (1:1:1) by flow cytometry shown in
(C). Note that shRNA against IFITM1 knocks down
both IFITM1 and IFITM3, shRNA against IFITM2
only knocks down IFITM2, and shRNA against
IFITM3 knocks down all three IFITMs. Next, the
cells were infected with HIV-1NL43-iGFP bearing
VSV-G, which served as donor cells, and cocul-
tured with target Jurkat cells stably expressing
tdTomato (Jurkat/tdTomato). The cell-to-cell
infection efficiency was determined by measuring
GFP+ Jurkat cells 48 hr after coculture using flow
cytometry (D) and summarized in (E). *p < 0.05.
Results are from four independent experiments
performed in duplicates.
See also Figure S2.IFITM proteins and HIV-1 Env was also observed in PM1 cells
(Figure 3D), although knockdown of individual IFITMs in PM1
cells only modestly increased HIV-1 Env processing (Figures
S2B–S2D). Overall, these results demonstrated that IFITM
proteins, especially IFITM2 and IFITM3, specifically interact
with HIV-1 Env in viral producer cells, resulting in impaired Env
processing.
IFITM incorporation into HIV-1 virions has been recently re-
ported to be responsible for impaired viral infectivity (Compton
et al., 2014; Tartour et al., 2014). Hence, we compared the
incorporation efficiencies of IFITM1, IFITM2, and IFITM3 into
HIV-1 virions and examined their possible correlations between
incorporation efficiency and inhibitions of cell-to-cell infection.
Surprisingly, we found that all three IFITMs were abundantly
present in culture media, likely as exosomes, even in cells
not expressing HIV-1 (Figure 3E, right three lanes). To deter-148 Cell Reports 13, 145–156, October 6, 2015 ª2015 The Authorsmine if IFITMs are specifically incorporated into HIV-1 virions,
we adopted an approach that we recently used to evaluate
TIM-family protein incorporation (Li et al., 2014). We first immu-
noprecipitated purified HIV-1 virions using HIV-1 immunoglob-
ulin (HIV-Ig, pooled HIV patient sera), and we then performed
western blotting using anti-FLAG to detect IFITMs. We
observed that all IFITMs were detected in the pulled down
HIV-1 virions, consistent with reports of Compton and Tartout
et al. (Compton et al., 2014; Tartour et al., 2014). However,
IFITM1 was more abundantly incorporated into HIV-1 virions
compared to IFITM2 and 3 (Figure 3F, top panel), which is
not in accordance with their inhibition of cell-to-cell infection
and diminished infectivity (Figure 1); this was despite the equiv-
alent input of IFITMs (Figure 3G), as well as almost equivalent
virion pull-down efficiency by HIV-Ig (Figure 3F, bottom panel).
Notably, the signals of gp120 in the purified virions, either
Figure 3. IFITM Proteins Interact with HIV-1 Env and Impair its
Processing and Incorporation into Viral Particles
293T cells were transiently transfected with HIV-1NL43 in the presence or
absence of IFITM plasmids. The cells were lysed with a membrane-disrupting
RIPA buffer containing 0.1% SDS and 1% NP40, and lysates were immuno-
precipitated with anti-FLAG antibody.
(A) The expression of HIV-1 Env, Gag, and IFITMs in transfected cells was
examined by using anti-gp120, gp41, anti-p24, and anti-FLAG, respectively.
b-Actin serves as a loading control. The ratios of gp120 versus gp160 and
gp41 versus gp160 in the cell lysates were determined by quantifying the band
intensities of gp120, gp41, and gp160 using Quantity One (Bio-Rad).
(B) Detection of the interaction between IFITMs and HIV-1 Env in viral producer
cells. Western blotting was performed by using anti-gp120 (top panel) or anti-
gp41 (middle panel) to detect HIV-1 Env.
(C) Quantification of HIV-1 Env processing. The results represent average ±SD
of four independent experiments. **p < 0.01; ***p < 0.001.
(D) Endogenous IFITMs interact with HIV-1 Env in PM1 cells. PM1 cells were
infected with HIV-1NL43 or mock-infected, and cells were lysed by RIPA buffer
48 hr after infection. Lysates were subjected to immunoprecipitation using
pooled antibodies against IFITM1, 2, or 3, or with a normal rabbit Ig that serves
as negative control; western blots were performed using anti-gp41.
(E) Detection of IFITMs in supernatants of 293T cells not transfected with HIV-1
plasmid. Supernatants were concentrated by ultracentrifugation using 20%
sucrose, and pellets were analyzed by western blotting using anti-FLAG or
anti-p24.
Cbefore (referred to as ‘‘virion input’’) or after immunoprecipita-
tion with HIV-Ig (referred to as ‘‘IP: HIV-Ig’’), were substantially
reduced by IFITM expression, especially IFITM2 and 3 (Figures
3F and 3G), consistent with the lower levels of gp120 in the
cells. We also observed that gp160 in IFITM2 and IFITM3-con-
taining HIV-1 virion input was significantly increased (Figure 3G,
middle panel), which likely represents immature Env in microve-
sicles and/or exosomes, whose release might be promoted by
IFITM2 and 3. Together, our data support the conclusion that
IFITMs are abundantly present in the media of normally
cultured cells, even without HIV-1, which is consistent with a
recent study (Zhu et al., 2015), and that IFITM incorporation
into HIV-1 virions, although detected, does not strictly correlate
with the phenotype of IFITM inhibition of HIV-1 cell-to-cell
infection.
IFITM3 Protein Promotes HIV-1 gp120 Shedding
Next, we explored the possibility that IFITM proteins, in partic-
ular IFITM3, may trigger gp120 (SU) shedding in viral producer
cells, which could partly explain or contribute to the reduced
levels of gp120/gp41expression in the cell and viral particles
as well as impaired viral infectivity. Our previous work has
already demonstrated that IFITM3 does not significantly inhibit
HIV-1 production (Lu et al., 2011). We performed pulse-chase
labeling experiments using 293T cells transiently transfected
with HIV-1NL43, in the presence or absence of IFITM3, and
then measured gp120 shedding into culture media by immuno-
precipitation using HIV-Ig. While the expression of gp160
decreased in a time-dependent manner, as would be expected,
the level of gp160 in IFITM3-expressing cells suffered a more
rapid decrease compared to cells expressing HIV-1 NL43 alone
(Figures 4A and 4B). In contrast, HIV-1 Gag (Pr55) expression in
both cell groups exhibited similar rates of decline, regardless of
IFITM3 expression or not (Figures 4A and 4C). Notably, we
consistently observed an enhanced SU shedding in IFITM3-ex-
pressing cells compared to cells expressing HIV-1 NL43 alone,
especially at 2, 4, and 6 hr of the chase labeling time (Figures
4A and 4D). Overall, the pulse-chase labeling data indicate
that IFITM expression in viral producer cells likely increases
gp160 turnover and promotes gp120 shedding into culture
media.
The IFITM C Terminus Contributes to Inhibition of HIV-1
Cell-to-Cell Transmission and Viral Membrane Fusion
Given strong similarities among the three human IFITM proteins,
it is interesting that IFITM1 is much less potent than IFITM2 and(F and G) IFITMs are incorporated into HIV-1 virions with different efficiencies,
which do not correlate with their phenotypes in inhibiting HIV-1 cell-to-cell
infection. Viral supernatants were concentrated from cells used for Figures 3A
and 3B by ultracentrifugation (20% sucrose), followed by immunoprecipitation
(IP) using HIV-Ig. Western blotting was performed by using anti-FLAG (to
detect IFITMs), anti-gp120, or anti-p24. The gp120 band intensities were
quantified byQuantity One, with relative values to the vector control indicated.
No IFITM protein can be pulled down by HIV-Ig from concentrated supernatant
of cells not expressing IFITMs (data not shown). Results represent three
independent experiments.
See also Figure S3.
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Figure 4. IFITM3 Protein Promotes HIV-1
gp120 Shedding and Increased gp160
Turnover
HEK293T cells were transfected with plasmids
encoding HIV-1 NL4-3 provirus in the presence or
absence of IFITM3. Cells were pulse-labeled with
35S-Met/Cys at 37C for 1 hr and chased in unla-
beled medium for the times indicated. The cell
lysates and supernatants were immunoprecipi-
tated with HIV-Ig at 4C overnight and separated
by SDS-PAGE.
(A) Representative phosphorimages of cell lysates
(top) and supernatants (bottom) from three inde-
pendent experiments are shown.
(B–D) Quantifications of the phosphorimaging in-
tensity of HIV-1 gp160 (B), Gag Pr55 (C), and shed
gp120 (D). Note that in (B) and (C), we set the
signals of HIV-1 gp160 or Gag Pr55 in the absence
and presence of IFITM3 to 1.0, respectively. In (D),
we set the signal of gp120 in the absence of
IFITM3 at 6 as 1.0 for comparison.IFITM3 at inhibiting HIV-1 viral infectivity and cell-to-cell trans-
mission. We therefore examined several IFITM1/IFITM2 chi-
meras that we had previously generated; they differ primarily at
the N and C termini (Li et al., 2015). Chimeric IFITM1112 and
IFITM1222 contain the N terminus of IFITM1 and the C terminus
of IFITM2, whereas chimeric IFITM2221 and IFITM2111 contain
the N terminus of IFITM2 and the C terminus of IFITM1 (Li et al.,
2015). We found that IFITM1112 and IFITM1222 strongly in-
hibited HIV-1 cell-to-cell infection, with efficiency similar to, or
even higher than, that of IFITM2 (Figure 5A). In contrast, chi-
meras IFITM2221 and IFITM2111 showed modest inhibitions of
HIV-1 cell-to-cell infection, almost identical to the phenotype
of IFITM1 (Figure 5A). These data suggest that the C terminus
of IFITM1 intrinsically suppresses inhibition of HIV-1 transmis-
sion from 293T to Jurkat cells. The negative impact of the C ter-
minus of IFITM1 on inhibition of HIV-1 cell-to-cell transmission
was further supported by the phenotypes of three IFITM1 trunca-
tion mutants (Li et al., 2015), i.e., D(108–125), D(112–125), and
D(117–125), all of which exhibited enhanced inhibition of HIV-1
cell-to-cell transmission compared to WT IFITM1 (Figure 5A).
The differential effects of IFITM chimeras as well as IFITM1
deletion mutants on HIV-1 cell-to-cell transmission seemed to
correlate with their capability to associate with HIV-1 Env. For
example, chimeric IFITM1112 and 1222 exhibited increased
associations with HIV-1 Env relative to IFITM1 WT (Figure S3).
The increased interaction was also observed for three IFITM1
C-terminal deletion mutants, e.g., D(117–125), despite their
apparent downregulation of HIV-1 Env (Figure S3). Collectively,
these results suggest that the C terminus of IFITM1 intrinsically
suppresses association with HIV-1 Env, and this likely contrib-
utes to and explains, at least in part, its less potent ability to block
cell-to-cell transmission.
We also examined several N-terminal point mutations or dele-
tions of IFITM3, which had been previously shown to affect post-
translational modification and endocytic trafficking of IFITM3 (Jia
et al., 2012, 2014). However, we did not observe significant dif-
ferences between these mutants and parental IFITM3 in inhibit-150 Cell Reports 13, 145–156, October 6, 2015 ª2015 The Authorsing HIV-1 cell-to-cell transmission (Figure 5B), despite the fact
that some of these constructs exhibited increased expression
on the cell surface (Jia et al., 2012, 2014) (data not shown). The
total protein expression of these IFITM1/2 chimeras and IFITM3
mutants had been previously shown to be comparable to their
parental IFITM1, 2, or 3 (Jia et al., 2014; Li et al., 2015; Lu
et al., 2011). Taken together, these results revealed that the C
termini of IFITM proteins regulate their inhibitory effects on
HIV-1 cell-to-cell transmission.
To directly measure the effect of IFITM expression on virion-
cell fusion, we next performed HIV-1 BlaM-Vpr viral fusion
assays in our cell-to-cell infection system. 293T cells were co-
transfected with NL43 proviral DNA plus a plasmid expressing
BlaM-Vpr, in the presence or absence of IFITMs. We cocultured
the transfected 293T cells with target Jurkat cells stably express-
ing tdTomato (Jurkat/tdTomato); 2 hr after coculture, HIV-1
fusion within target Jurkat/tdTomato cells was measured by
gating the tdTomato-positive population using flow cytometry.
As shown in Figure 5C, expression of IFITMs, especially IFITM2
and IFITM3, in donor 293T cells substantially inhibited HIV-1
fusion (likely a mix of virus-cell and cell-cell fusion) in Jurkat/
tdTomato cells, correlating with their effects on cell-to-cell infec-
tion (Figure 1B). Consistent with the negative influence of the C
terminus of IFITM1 on inhibiting cell-to-cell infection shown in
Figure 5A, chimeras IFITM1112 and IFITM1222, but not those
of IFITM2221 and IFITM2111, effectively inhibited HIV-1 fusion
in target cells to a similar extent as IFITM2 and IFITM3
(Figure 5C).
Given the above finding that HIV-1 Env is directly affected by
IFITMs, we next carried out cell-cell fusion assays by transfect-
ing 293T cells with plasmids encoding HIV-1 Env and Tat along
with IFITMs; these cells were then cocultured with HeLa-TZM,
and cell-cell fusion was quantified by measuring the firefly lucif-
erase activity of cocultured cells. In particular, we compared
the cell-cell fusion efficiency of HIV-1 Env when IFITM proteins
are expressed at similar levels in effector 293T cells, the
target HeLa-TZM cells (stably expressing IFITMs by retroviral
Figure 5. The IFITM C Terminus Regulates
the Inhibition of HIV-1 Cell-to-Cell Infection
and Membrane Fusion
(A and B) Effect of IFITM1/2 chimeras and IFITM3
N-terminal mutants on HIV-1 cell-to-cell infection.
The experiments were performed using 293T as
donor cells and Jurkat as target cells.
(C) Effect of parental IFITMs and IFITM1/2 chi-
meras on HIV-1 virion fusion during cell-to-cell
infection. Note that the HIV-1 BlaM-Vpr-based
fusion assay was implemented into cell-to-cell
infection experiments (see details in Experimental
Procedures).
(D and E) Effect of IFITMs and chimeras on HIV-1
Env-mediated cell-cell fusion. 293T cells were
transfected with HIV-1NL43 along with LXSN that
encodes HIV-1 Tat, in the presence or absence of
IFITMs. The transfected 293T cells (effector cells)
were cocultured with parental HeLa-TZM or HeLa-
TZM stably expressing IFITMs (target cells) for 12–
24 hr. Cells were lysed, proteins were quantified,
and firefly activity was measured. All samples
were done in duplicate. Results shown represent
three to four independent experiments.
(F) Effect of IFITMs in effector cell, target cells, or
both on IAV HA-mediated cell-cell fusion. Assays
were carried out as described in (D) and (E), except
that IAV HA was tested and cocultured cells were
treated with pH 5.0 for 1 min following coculture.
Results represent three to four independent
experiments.
For all figures, relative numbers are presented.
*p < 0.05; **p < 0.01; ***p < 0.001.transduction), and both. Consistent with previously published
data (Compton et al., 2014), expression of IFITMs, especially
IFITM2 and IFITM3, in effector cells, but to a much lesser extent
in target cells, inhibited cell-cell fusion induced by HIV-1NL43 Env
protein (Figure 5D). Extending these results, and in agreement
with the cell-to-cell infection (Figure 5A) and virion-cell fusion
data (Figure 5C), chimeric IFITM1112 and IFITM1222, but not
IFITM2221 and IFITM2111, potently inhibited HIV-1NL43 Env-
mediated cell-cell fusion (Figure 5E). In stark contrast to the
strong inhibitory effect of IFITM expression in effector cells on
HIV-1 Env, we found that cell-cell fusion mediated by influenza
A virus (IAV) HA was equivalently inhibited by IFITM expression
in effector cells and target cells (Figure 5F), similar to our previ-
ous results obtained with Jaagsiekte sheep retrovirus (JSRV)
Env (Li et al., 2013). Altogether, these results strengthen the
notion that IFITMs specifically antagonize the HIV-1 Env protein
to inhibit viral cell-to-cell infection, and that this mechanism is
distinct from the IFITM inhibition of IAV hemagglutinin (HA) and
JSRV Env (Li et al., 2013).Cell Reports 13, 145–15HIV-1 Adapts to Overcome IFITM
Restriction of Cell-to-Cell Infection
by Acquiring Mutations in Env
We previously reported that mutations in
HIV-1 Env were able to overcome IFITM-
mediated restriction of HIV-1 replication
(Ding et al., 2014). Next, we sought toextend these results to the IFITM constructs under analysis
here. Given the apparently enhanced ability of IFITM1D(117–
125) to inhibitHIV-1NL43cell-to-cell infectioncompared toparental
IFITM1,weperformed long-term replication assays andobserved
that, indeed, IFITM1D(117–125) and IFITM1D(108–125) mutants
profoundly inhibited HIV-1NL43 replication compared to WT
IFITM1 (Figure 6A). We then carried out virus evolution experi-
ments to interrogate if HIV-1 can escape from the inhibition of
IFITM1D(117–125) following a seriesof prolongedpassages. After
3 weeks of culturing HIV-1NL43 in IFITM1D(117–125)-expressing
SupT1 cells, we observedpronounced cytopathic effects accom-
panied by increased viral RT activity in the culture supernatants,
implying the possible emergence of HIV-1 escape mutants. We
recovered the viral DNA from infected cells and identified two
mutations: a stop codon at the 40th amino acid position in Vpu
(Vpu40), which caused Vpu truncation, and an alanine-to-valine
change at residue 539 in Env (EnvA539V). While the Vpu40 or
EnvA539V alone marginally increased the replication of HIV-
1NL4-3 in IFITM1D(117–125)-expressing SupT1 cells (Figure 6B),6, October 6, 2015 ª2015 The Authors 151
Figure 6. Mutations in the HIV-1 env Gene
Provide Escape from IFITM-Mediated Inhi-
bition of Viral Replication and Cell-to-Cell
Infection
(A) Replication kinetics of HIV-1NL43 in SupT1 cells
expressing IFITM1 WT or its two mutants,
IFITM1D(117–125) and IFITM1D(108–125). The
expression of IFITM1 and its mutants in the cells
was induced by doxycycline (Dox) (500 ng/ml),
viral replication was determined by measuring the
levels of viral RT activity in culture supernatants.
(B) Replication kinetics of HIV-1NL43 WT and mu-
tants Vpu40, EnvA539V, and Vpu40/EnvA539V in
SupT1 cells expressing (with Dox) or not ex-
pressing IFITM1D(117–125) (without Dox).
(C) Effect of IFITMs on cell-to-cell infection of
HIV-1 escape mutants. Experiments were per-
formed as described in the legend of Figures 1A–
1C, except HIV-1NL43 mutants Vpu40, EnvA539V,
and Vpu40/EnvA539V bearing VSV-G were used
for infection of Jurkat/inGLuc cells, which served
as donors. Because of the difference between WT
and HIV-1 mutants in infectivity in the absence of
IFITMs, we plotted the absolute Gluc readouts
(RLU) in this and other related figures.
(D) Effect of IFITMs on Jurkat-to-Jurkat transfer
mediated by the Env cytoplasmic tail deletion
mutant (NL43 EnvDCT).
(E) Effect of IFITMs on 293T-to-Jurkat transfer of
NL43 EnvDCT. (F) Effect of IFITMs on cell-cell
fusion (between 293T expressing Env and HeLa-
TZM) mediated by the Env protein of NL43
EnvDCT.
For all data shown in (A)–(F), results shown
represent at least three independent experiments.
*p < 0.05; **p < 0.01; ***p < 0.001. See also Fig-
ure S4.the double mutant Vpu40/EnvA539V allowed virus replication to
peak at day 12 in D(117–125)-expressing SupT1 cells compared
to the replication peak at day 8 in control SupT1 cells, which sug-
gests a partial restoration of virus replication (Figure 6B). Consis-
tentwith this result, theVpu40mutantdidnotappear toexhibit any
difference from WT HIV-1 in sensitivity of IFITM inhibition of cell-
to-cell infection; however, EnvA539V, as well as the double
mutant containing both Vpu40 and EnvA539V, substantially,
though not completely, overcame the inhibition by IFITMs (Fig-
ure 6C). These results demonstrated that HIV-1 can acquire
escapemutations that evade IFITM restriction, further supporting
the notion that IFITMs antagonize HIV-1 Env to inhibit viral cell-to-
cell infection, although these mutants may not be IFITM-specific
(see below).
Truncation of the cytoplasmic tail of HIV-1 Env is known to in-
crease cell-cell fusion, possibly by changing the conformation of
the Env’s extracellular domain (Freed and Martin, 1994, 1996;
LaBranche et al., 1995). We thus examined the effect of IFITMs
on truncated HIV-1NL43 Env, in which the last 144 amino acids
of the C terminus was deleted (NL43 EnvCTdel-144) (Freed
and Martin, 1996; Murakami and Freed, 2000). Interestingly,
we found that IFITMs did not inhibit Jurkat-to-Jurkat and 293-
to-Jurkat transfer of NL43 EnvCTdel-144 as potently as they
did the WT, despite the reduced infectivity of this mutant relative152 Cell Reports 13, 145–156, October 6, 2015 ª2015 The Authorsto that of HIV-1NL43 WT (Figures 6D and 6E) (Murakami and
Freed, 2000). We next analyzed cell-cell fusion by transfecting
293T cells with an Env-expression construct derived from
NL43 EnvCTdel-144 and using HeLa-TZM as target cells, again
with a similar trend of inhibition obtained (Figure 6F). Note that
the cell-cell fusion activity of NL43 EnvCTdel-144 is relatively
higher than the WT in the absence of IFITM (Figure 6F), consis-
tent with numerous previously published reports. Altogether,
these results showed that deletion of the cytoplasmic tail of
HIV-1 Env can overcome the restriction of IFITMs on cell-to-
cell infection and cell-cell fusion.
To determine whether IFITM proteins, especially IFITM3, have
altered capability to inhibit the processing of A539V and CTdel-
144 mutants, and to determine whether or not IFITM3 still
interacts with them, we carried out coimmunoprecipitation ex-
periments as described for the WT HIV-1NL43. We found that
the processing of Env A539V mutant was still inhibited by
IFITM3, as evidenced by increased gp160 and decreased
gp120 and gp41 in the cell lysates, and that A539V also inter-
acted with IFITM3 as efficiently as did the WT Env (Figure S4A,
top two panels). These suggest that A539V mutant likely arose
by gaining replication fitness. Notably, we found that CTdel-
144 Env had substantially lost its capability to associate with
IFITM3 (Figure S4A, bottom panels). Furthermore, we observed
Figure 7. The Ability of IFITMs to Inhibit
Cell-to-Cell Infection/Fusion by HIV-1
BH10, YU2, AD8, HIV-2, and SIVs Are
IFITM-Species and Virus-Strain Dependent
293T cells were transfected HIV-1 proviral DNAs
encoding BH10, YU2, NL43(AD8) (abbreviated
AD8), NL43 along with a VSV-G-expressing
plasmid (A) and (B), or the molecular clones of
HIV-2 or SIVs (C) and (D). For HIV-1 (A) and (B), the
produced viruses were used to infect Jurkat/
inGLuc cells overnight, and after thorough
washing with PBS, the infected Jurkat/inGLuc
cells were cocultured with Jurkat cells (for BH10
and NL43) or CD4+ PBMCs (for YU2 and AD8). For
HIV-2 and SIVs (C and D), the transfected 293T
cells were cocultured with HeLa-TZM. Cell-to-cell
infection/fusion efficiency was determined by
measuring GLuc (A) or firefly luciferase activity (D)
24–48 hr after coculture. Cell-free viral infection
was performed in parallel, with exactly the same
numbers of normal donor plus target cells as
described in the text and Experimental Pro-
cedures (B and D). **p < 0.01; ***p < 0.001.
Because different HIV and SIV isolates have
different infectivities in the absence of IFITMs, we
also plotted the data using absolute Gluc readouts
shown in Figures S5A–S5D. For comparisons be-
tween cell-to-cell and cell-free viral infection,
please refer to Figures S5E and S5F.a comparable gp41/g160 ratio for CTdel-144 in cells expressing
or not expressing IFITM3 (Figure S4A) as well as comparable
gp120 levels in virions produced by the NL4-3/CTdel-144mutant
(Figure S4B). These results demonstrate that IFITM3 has a
smaller effect on the CTdel-114 mutant as compared to the
HIV-1NL43 WT. Altogether, these data suggest that the CT of
HIV-1 Env is critical for Env association with IFITM3 and that
the A539V Env escape mutant is more fit than WT and is thus
able to non-specifically overcome IFITM restriction.
IFITMs Inhibit Cell-to-Cell Infection/Fusion of HIV-2 and
SIVs in a Species-Specific Manner
We further determined the ability of IFITMs to inhibit cell-to-cell
infection by other strains of HIV-1, including some primary iso-
lates, as well as by some commonly used HIV-2 and SIV isolates.
Similar to HIV-1NL43, the transmission of HIV-1BH10 and AD8 from
Jurkat/inGLuc to parental Jurkat cells or PBMCswas strongly in-
hibited by IFITMs, especially IFITM2 and IFITM3 (Figures 7A and
S5A). Interestingly, the transmission of primary isolate YU2 from
Jurkat/inGLuc cells to primary PBMCs was solely inhibited by
IFITM2 and IFITM3, but not at all by IFITM1 (Figures 7A and
S5A). Surprisingly, and distinct from NL43, the cell-free infection
of BH10, YU2 and AD8 was almost equivalently inhibited by
three IFITMs (Figures 7B and S5B). In all cases, cell-to-cell infec-
tion was more efficient than cell-free infection, although the fold
differences were virus-strain dependent (Figure S5E).
Because, like HIV-1, HIV-2 and SIVs use either CCR5 or
CXCR4 coreceptors for infection in addition to CD4, for
simplicity, we decided to use HeLa-TZM, which are permissive
to both HIV-2 and SIVs, as target cells. We thus transfected
293T cells withmolecular clones of HIV-2Rod-1, SIVagm, SIVmac,Cor SIVcpz, and cocultured the transfected 293T cells with HeLa-
TZM; the cell-to-cell infection/fusion and cell-free viral infection
of these viruses were measured in parallel as described above.
The cell-to-cell infection/fusion mediated by SIVcpz and SIVagm
were greatly inhibited by IFITMs, especially IFITM2 and 3; how-
ever, the cell-to-cell infection/fusion of SIVmac was unaffected,
despite similar infection efficiencies in mock cells transfected
with an empty pQCXIP vector (Figures 7C and S5C). Notably,
the cell-free infection of SIVagm was profoundly inhibited by all
three IFITMs (>20-fold) compared to SIVcpz, SIVmac, and
HIV-2, which weremodestly inhibited by the three human IFITMs
(Figures 7D and S5D). Similar to HIV-1, the cell-to-cell infection/
fusion of HIV-2 and SIVs aremore efficient than cell-free infection
(Figure S5F). However, we cannot rule out the possibility that the
differences between cell-to-cell and cell-free infection for SIVcpz
and HIV-2 were due to their extremely low cell-free infection in
HeLa-TZM cells. Altogether, these results demonstrated that
while cell-to-cell infection/fusion of CCR5-using HIV-1 YU2 and
AD8, as well as HIV-2 and SIVs, are inhibited by human IFITMs,
the extents of inhibition differ depending on the specific IFITMs
and the viruses tested.
DISCUSSION
Cell-to-cell transfer by HIV-1 is a more efficient means of infec-
tion than cell-free infection and is likely the dominant route of
HIV-1 infection in vivo (Dale et al., 2013; Zhong et al., 2013).
Here, we provide evidence that IFITM proteins inhibit HIV-1
cell-to-cell infection by antagonizing Env, thus clarifying the
mechanism by which IFITMs restrict HIV and possibly other
viruses. During the preparation of our manuscript, a paper byell Reports 13, 145–156, October 6, 2015 ª2015 The Authors 153
Compton et al. was published showing that IFITMs are incorpo-
rated into HIV-1 virions thus impairing the viral spread through
cell contact; however, the exact underlying mechanism was
not determined (Compton et al., 2014). While the incorporation
of IFITMs into HIV-1 virions was confirmed in our work, we did
not observe a strict correlation between levels of IFITM incorpo-
ration and inhibition of cell-to-cell infection. For example, despite
its high levels in HIV-1 particles, IFITM1 in general displayed the
lowest inhibitory activity among the three human IFITMs. Signif-
icantly, we discovered that IFITM proteins interact with HIV-1
Env in viral producer cells, impair Env processing, and promote
SU shedding that altogether reduce virion fusion activity. While
we find that IFITMs also inhibit the cell-to-cell infection/fusion
of HIV-2 and SIVs, the extents of inhibition are both IFITM- and
virus-species dependent. We were able to confirm and extend
our previous finding (Ding et al., 2014) that HIV-1 can adapt to
overcome the IFITM restriction by mutating its env gene during
prolonged replication. Hence, results from our study offer in-
sights into understanding the mechanisms of IFITM restriction
of viral infection as well as HIV-host co-evolution.
How can the expression of IFITMs in donor cells, rather than in
target cells, inhibit HIV-1 cell-to-cell infection? One obvious pos-
sibility is that IFITM proteins somehow modulate HIV-1 gene
expression and/or their functions in viral producer cells, resulting
in reduced viral output and/or defective virions. Alternatively,
IFITMs may modulate the expression of HIV-1 receptor, core-
ceptors, and/or even cellular adhesion molecules, such as
ICAM-1 or LFA-1, all of which are known to be important for for-
mation of the virological synapse (VS) and therefore cell-to-cell
infection. However, our flow cytometric analyses did not show
significant changes in CD4, CXCR4, CD63, CD81, ICAM-1, or
LFA-1 on the cell surface upon IFITM overexpression (Figure S6).
Additionally, at the early stage of cell-to-cell infection (e.g., 4 hr),
HIV-1 Gag-iGFP or iCherry can be transferred from donor to
target cells with similar efficiency between mock and IFITM-ex-
pressing cells (Figures S7A and S7B), further arguing against an
IFITM-mediated block in VS formation. By using an Amnis flow
cytometric imaging system (Swartz et al., 2014), we also
observed comparable stable associations between donor Jurkat
expressing or not expressing IFITMs with target PBMCs (Fig-
ure S7C), again suggesting that the formation of the VS is not
affected by IFITMs.
We provide evidence that IFITM proteins, especially IFITM2
and IFITM3, specifically interact with HIV-1 Env, resulting in
impaired Env processing and incorporation into HIV-1 virions,
which correlates with their inhibition of HIV-1 cell-to-cell infec-
tion. This mechanism of action is apparently distinct from that
observed in the context of IAV, JSRV, and possibly other viruses
in cell-free viral infections (Perreira et al., 2013). Previously, we
and others have shown that IFITM proteins inhibit cell-cell fusion
induced by a variety of viral fusion proteins on the plasma mem-
brane and that IFITMs can also block the virus-cell fusion in en-
dosomes (Desai et al., 2014; Li et al., 2013). We demonstrated
that expression of IFITMs in effector cells is as potent as their
expression in target cells in inhibiting Jaagsiekte sheep retro-
virus (JSRV) Env-mediated cell-cell fusion (Li et al., 2013). In
the current study, we extended this finding by showing that
cell-cell fusion induced by IAV HA is also equivalently inhibited154 Cell Reports 13, 145–156, October 6, 2015 ª2015 The Authorsby IFITM expression in effector and target cells. These results
are in striking contrast to what we have found for HIV-1, where
IFITMs must be present in effector or donor cells in order to effi-
ciently inhibit HIV-1 Env-mediated cell-cell fusion and cell-to-cell
infection. In addition to the impaired processing of HIV-1 Env, we
also find that IFITM3 promotes HIV-1 SU shedding into culture
media. This observation, together with our data showing that
IFITM proteins specifically interact with HIV-1 Env gp41, sug-
gests that IFITM proteins, especially IFITM2 and 3, may alter
the conformation of HIV-1 Env and likely result in premature trig-
gering and impaired infectivity. The increased rate of gp160 turn-
over observed here also suggests that IFITM-bound gp160 may
be targeted for degradation. Work is ongoing to determine the
detailed interactions between IFITMs and HIV-1 Env as well as
possible conformational changes in Env.
Similar to the escape of HIV-1BH10 from IFITM1 inhibition that
we recently reported (Ding et al., 2014), we demonstrated in this
work that HIV-1NL43 also mutates Vpu and Env to overcome the
inhibition not only by IFITM1D(117–125) mutant, from which
these mutants were selected, but also by the parental IFITM1,
2, and 3. Interestingly, both HIV-1BH10 and HIV-1NL43 acquired
mutations in Vpu that caused the production of a truncated
Vpu of 33–39 amino acids. However, the escape mutations in
Env differ considerably between these two viruses. HIV-1BH10
has the G367E mutation that attenuates the binding of Env to re-
ceptor CD4 and therefore profoundly diminishes the infectivity of
HIV-1BH10. In the case of HIV-1NL43, the A539 residue within hep-
tad repeat 1 (HR1) of gp41 was changed to a valine. However,
preliminary data show that the A539V Env mutant still interacts
with IFITM proteins (Figure S4A), indicating that additional mech-
anisms are involved. While the escape mutants we discovered
may not be specific for IFITMs, these data support an active
role of Env in overcoming host restrictions of HIV-1 infection.
It is interesting that, despite strong sequence similarity be-
tween IFITM1 and IFITM2/3, IFITM1 shows a relatively weak abil-
ity to inhibit HIV-1 cell-to-cell infection as compared to IFITM2
and 3, especially from 293T to Jurkat cells. By examining the chi-
meras between IFITM1 and IFITM2, we discovered that theC ter-
minusof IFITM1 inherently suppresses the inhibitionofHIV-1 cell-
to-cell infection while the N terminus does not play a major role.
Further deletion mutants revealed that the C-terminal nine amino
acids of IFITM1are sufficient to confer this effect.While it remains
to be determined how exactly these nine residues determine the
differential effects of IFITMs on HIV-1 cell-to-cell infection, it is
possible that deletion of the last nine amino acids may change
the conformation or the topology of IFITM1, rendering it capable
of interacting with HIV-1 Env as does IFITM3. It is also possible
that the predominant localization of IFITM1 is different from that
of IFITM2 and IFITM3 in the cell, and this may be determined, in
part, by the C terminus of IFITM1, which could interact with other
cellular factors involved in HIV-1 cell-to-cell transmission (Pur-
year et al., 2013; Roy et al., 2014;Wen et al., 2014). Future exper-
iments will address these possibilities.EXPERIMENTAL PROCEDURES
Plasmids, Cells, and Reagents
Details are described in the Supplemental Experimental Procedures.
Transfection, Virus Production, and Infection
Cells were transfected for viral production and infection as described in the
Supplemental Experimental Procedures.
Cell-to-Cell Infection
Cell-to-cell infection was performed in several setups, including (A) HEK293T-
to-Jurkat cells, (B) T cell-to-T cells, (C) PBMCs-to-T cells, and (D) T cell to
PBMCs. For Jurkat cell to other T cell transmission, we use an HIV-1NL43-intron
Gaussia-basedsystem,whichwasoriginally describedbyDerseandcolleagues
(Mazurov et al., 2010). This assay takes advantage that an intron, which was in-
serted into an HIV-1 vector in an opposite orientation to the Luc open reading
frame, can be removed upon lentiviral vector transduction of target cells; the
Gluc gene is not expressed in transfected or infected donor cells. Briefly, we in-
fected Jurkat/inGLuc cells expressing or not expressing IFITMs, or PM1 cells
stably expressing shRNA IFITMs or scramble RNA, with VSV-G pseudotyped
HIV-1NL43. The VSV-G pseudotyped HIV-1 was used because it can efficiently
infect donor cells (almost 100%) and therefore enhance our capability of detect-
ing cell-to-cell infection. Target cells include Jurkat, HeLa-TZM, and PBMCs;
24–48 hr after coculture or infection, GLuc activity was measured for cell-to-
cell infection and cell-freeHIV-1 infection. In all cases, no effect of IFITMexpres-
sion on cell viability or proliferation capacity of the donor cells was found.
Detailed information is provided in the Supplemental Experimental Procedures.
Live-Cell Imaging
The procedures are outlined in the Supplemental Experimental Procedures.
Immunoprecipitation and Western Blotting
Western blotting and IP was performed as previously described (Co^te´ et al.,
2012; Liu et al., 2003). In particular, we used a RIPA buffer (50 mM Tris [pH
7.5], 150mMNaCl, 1 mMEDTA, 1%Nonidet P-40, 0.1% SDS), which disrupts
membrane-associated proteins, to lyse cells. The detailed steps are outlined in
the Supplemental Experimental Procedures.
Pulse-Chase Labeling, Cell-to-Cell Virion Fusion, and Cell-Cell
Fusion
Details are provided in the Supplemental Experimental Procedures.
Cell Surface or Intracellular Staining by Flow Cytometry
Cells were washed and incubated with different primary antibodies for 1 hr.
After incubation with secondary antibodies, cells were analyzed by flow cy-
tometry (see details in the Supplemental Experimental Procedures).
Viral Replication and Selection of HIV-1 Escape Mutants
The experiments were carried out described in the Supplemental Experimental
Procedures.
Statistical Analysis
All statistical analyses were carried out in GraphPad Prism5, with Student’s
t tests or one-way ANOVA used unless otherwise noted. Typically, data from
three to five independent experiments were used for the analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.08.055.
AUTHOR CONTRIBUTIONS
J.Y. and M.L. contributed equally to this manuscript. J.Y. performed most ex-
periments. M.L carried out key initial experiments leading to critical conclu-
sions. J.W. performed live-cell imaging and quantified cell-to-cell infection.
S.D. carried out selection of HV-1 escape mutants. T.H.S. and A.M.E. per-
formed cell-to-cell infection using Amnis flow cytometry. Y.-M.Z. made essen-
tial IFITM constructs. J.Y., M.L., E.O.F., C.L., B.K.C., and S.-L.L. analyzed and
interpreted data, assembled the figures, and wrote the manuscript.CACKNOWLEDGMENTS
We thank Walther Mothes for provision of the Jurkat/inGLuc cells that made
this work possible. We also thank the NIH AIDS reagent program for supplying
important reagents. We thank Boris Hartmann for help with Amnis flow cyto-
metric experiments. This work was supported by NIH grants to S.-L.L.
(AI112381, AI109464, AI105584, and AI107095) and B.K.C. (GM113885 and
DA028866) as well as by Canadian Institutes of Health Research (CIHR)
(C.L.). Research in the Freed lab is supported by the Intramural Research Pro-
gram of the Center for Cancer Research, National Cancer Institute, NIH, and by
the Intramural AIDS Targeted Antiviral Program.
Received: March 13, 2015
Revised: June 16, 2015
Accepted: August 19, 2015
Published: September 17, 2015
REFERENCES
Agosto, L.M., Zhong, P., Munro, J., and Mothes, W. (2014). Highly active anti-
retroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS
Pathog. 10, e1003982.
Amini-Bavil-Olyaee, S., Choi, Y.J., Lee, J.H., Shi, M., Huang, I.C., Farzan, M.,
and Jung, J.U. (2013). The antiviral effector IFITM3 disrupts intracellular
cholesterol homeostasis to block viral entry. Cell Host Microbe 13, 452–464.
Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M.,
Ryan, B.J., Weyer, J.L., van der Weyden, L., Fikrig, E., et al. (2009). The IFITM
proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus,
and dengue virus. Cell 139, 1243–1254.
Chesarino, N.M., McMichael, T.M., Hach, J.C., and Yount, J.S. (2014). Phos-
phorylation of the antiviral protein interferon-inducible transmembrane protein
3 (IFITM3) dually regulates its endocytosis and ubiquitination. J. Biol. Chem.
289, 11986–11992.
Chutiwitoonchai, N., Hiyoshi, M., Hiyoshi-Yoshidomi, Y., Hashimoto, M., To-
kunaga, K., and Suzu, S. (2013). Characteristics of IFITM, the newly identified
IFN-inducible anti-HIV-1 family proteins. Microbes Infect. 15, 280–290.
Compton, A.A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., Liang,
C., Casartelli, N., and Schwartz, O. (2014). IFITM proteins incorporated into
HIV-1 virions impair viral fusion and spread. Cell Host Microbe 16, 736–747.
Co^te´, M., Zheng, Y.M., Li, K., Xiang, S.-H., Albritton, L.M., and Liu, S.-L. (2012).
Critical role of leucine-valine change in distinct low pH requirements for mem-
brane fusion between two related retrovirus envelopes. J. Biol. Chem. 287,
7640–7651.
Dale, B.M., Alvarez, R.A., andChen, B.K. (2013). Mechanisms of enhancedHIV
spread through T-cell virological synapses. Immunol. Rev. 251, 113–124.
Desai, T.M., Marin, M., Chin, C.R., Savidis, G., Brass, A.L., and Melikyan, G.B.
(2014). IFITM3 restricts influenza A virus entry by blocking the formation
of fusion pores following virus-endosome hemifusion. PLoS Pathog. 10,
e1004048.
Diamond, M.S., and Farzan, M. (2013). The broad-spectrum antiviral functions
of IFIT and IFITM proteins. Nat. Rev. Immunol. 13, 46–57.
Ding, S., Pan, Q., Liu, S.L., and Liang, C. (2014). HIV-1 mutates to evade
IFITM1 restriction. Virology 454-455, 11–24.
Freed, E.O., and Martin, M.A. (1994). HIV-1 infection of non-dividing cells.
Nature 369, 107–108.
Freed, E.O., andMartin, M.A. (1996). Domains of the human immunodeficiency
virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorpora-
tion into virions. J. Virol. 70, 341–351.
Goujon, C., Moncorge´, O., Bauby, H., Doyle, T., Ward, C.C., Schaller, T., Hue´,
S., Barclay, W.S., Schulz, R., and Malim, M.H. (2013). Human MX2 is an inter-
feron-induced post-entry inhibitor of HIV-1 infection. Nature 502, 559–562.
Hrecka, K., Hao, C., Gierszewska, M., Swanson, S.K., Kesik-Brodacka, M.,
Srivastava, S., Florens, L., Washburn, M.P., and Skowronski, J. (2011). Vpxell Reports 13, 145–156, October 6, 2015 ª2015 The Authors 155
relieves inhibition of HIV-1 infection of macrophages mediated by the
SAMHD1 protein. Nature 474, 658–661.
Huang, I.C., Bailey, C.C., Weyer, J.L., Radoshitzky, S.R., Becker, M.M.,
Chiang, J.J., Brass, A.L., Ahmed, A.A., Chi, X., Dong, L., et al. (2011). Distinct
patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and
influenza A virus. PLoS Pathog. 7, e1001258.
Jia, R., Pan, Q., Ding, S., Rong, L., Liu, S.L., Geng, Y., Qiao, W., and Liang, C.
(2012). The N-terminal region of IFITM3modulates its antiviral activity by regu-
lating IFITM3 cellular localization. J. Virol. 86, 13697–13707.
Jia, R., Xu, F., Qian, J., Yao, Y., Miao, C., Zheng, Y.M., Liu, S.L., Guo, F., Geng,
Y., Qiao, W., and Liang, C. (2014). Identification of an endocytic signal essen-
tial for the antiviral action of IFITM3. Cell. Microbiol. 16, 1080–1093.
Jiang, D., Weidner, J.M., Qing, M., Pan, X.B., Guo, H., Xu, C., Zhang, X., Birk,
A., Chang, J., Shi, P.Y., et al. (2010). Identification of five interferon-induced
cellular proteins that inhibit west nile virus and dengue virus infections.
J. Virol. 84, 8332–8341.
Kane, M., Yadav, S.S., Bitzegeio, J., Kutluay, S.B., Zang, T., Wilson, S.J.,
Schoggins, J.W., Rice, C.M., Yamashita, M., Hatziioannou, T., and Bieniasz,
P.D. (2013). MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature
502, 563–566.
LaBranche, C.C., Sauter, M.M., Haggarty, B.S., Vance, P.J., Romano, J., Hart,
T.K., Bugelski, P.J., Marsh, M., and Hoxie, J.A. (1995). A single amino acid
change in the cytoplasmic domain of the simian immunodeficiency virus trans-
membrane molecule increases envelope glycoprotein expression on infected
cells. J. Virol. 69, 5217–5227.
Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Se´g-
e´ral, E., Yatim, A., Emiliani, S., Schwartz, O., and Benkirane, M. (2011).
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor
counteracted by Vpx. Nature 474, 654–657.
Li, K., Markosyan, R.M., Zheng, Y.-M., Golfetto, O., Bungart, B., Li, M., Ding,
S., He, Y., Liang, C., Lee, J.C., et al. (2013). IFITM proteins restrict viral mem-
brane hemifusion. PLoS Pathog. 9, e1003124.
Li, M., Ablan, S.D., Miao, C., Zheng, Y.M., Fuller, M.S., Rennert, P.D., Maury,
W., Johnson,M.C., Freed, E.O., and Liu, S.L. (2014). TIM-family proteins inhibit
HIV-1 release. Proc. Natl. Acad. Sci. USA 111, E3699–E3707.
Li, K., Jia, R., Li, M., Zheng, Y.M., Miao, C., Yao, Y., Ji, H.L., Geng, Y., Qiao,W.,
Albritton, L.M., et al. (2015). A sorting signal suppresses IFITM1 restriction of
viral entry. J. Biol. Chem. 290, 4248–4259.
Lin, T.Y., Chin, C.R., Everitt, A.R., Clare, S., Perreira, J.M., Savidis, G., Aker,
A.M., John, S.P., Sarlah, D., Carreira, E.M., et al. (2013). Amphotericin B in-
creases influenza A virus infection by preventing IFITM3-mediated restriction.
Cell Rep. 5, 895–908.
Liu, S.-L., Lerman, M.I., and Miller, A.D. (2003). Putative phosphatidylinositol
3-kinase (PI3K) binding motifs in ovine betaretrovirus Env proteins are
not essential for rodent fibroblast transformation and PI3K/Akt activation.
J. Virol. 77, 7924–7935.
Liu, Z., Pan, Q., Ding, S., Qian, J., Xu, F., Zhou, J., Cen, S., Guo, F., and Liang,
C. (2013). The interferon-inducible MxB protein inhibits HIV-1 infection. Cell
Host Microbe 14, 398–410.
Lu, J., Pan, Q., Rong, L., He, W., Liu, S.L., and Liang, C. (2011). The IFITM pro-
teins inhibit HIV-1 infection. J. Virol. 85, 2126–2137.
Mazurov, D., Ilinskaya, A., Heidecker, G., Lloyd, P., and Derse, D. (2010).
Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new
replication dependent vectors. PLoS Pathog. 6, e1000788.
Murakami, T., and Freed, E.O. (2000). The long cytoplasmic tail of gp41 is
required in a cell type-dependent manner for HIV-1 envelope glycoprotein
incorporation into virions. Proc. Natl. Acad. Sci. USA 97, 343–348.156 Cell Reports 13, 145–156, October 6, 2015 ª2015 The AuthorsNeil, S.J., Zang, T., and Bieniasz, P.D. (2008). Tetherin inhibits retrovirus
release and is antagonized by HIV-1 Vpu. Nature 451, 425–430.
Perreira, J.M., Chin, C.R., Feeley, E.M., and Brass, A.L. (2013). IFITMs restrict
the replication of multiple pathogenic viruses. J. Mol. Biol. 425, 4937–4955.
Puryear, W.B., Akiyama, H., Geer, S.D., Ramirez, N.P., Yu, X., Reinhard, B.M.,
and Gummuluru, S. (2013). Interferon-inducible mechanism of dendritic
cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. PLoS
Pathog. 9, e1003291.
Roy, N.H., Lambele´, M., Chan, J., Symeonides, M., and Thali, M. (2014). Ezrin
is a component of the HIV-1 virological presynapse and contributes to the
inhibition of cell-cell fusion. J. Virol. 88, 7645–7658.
Sadler, A.J., and Williams, B.R. (2008). Interferon-inducible antiviral effectors.
Nat. Rev. Immunol. 8, 559–568.
Schoggins, J.W., Wilson, S.J., Panis, M., Murphy, M.Y., Jones, C.T., Bieniasz,
P., and Rice, C.M. (2011). A diverse range of gene products are effectors of the
type I interferon antiviral response. Nature 472, 481–485.
Sheehy, A.M., Gaddis, N.C., Choi, J.D., and Malim, M.H. (2002). Isolation of a
human gene that inhibits HIV-1 infection and is suppressed by the viral Vif pro-
tein. Nature 418, 646–650.
Smith, S., Weston, S., Kellam, P., andMarsh, M. (2014). IFITM proteins-cellular
inhibitors of viral entry. Curr. Opin. Virol. 4, 71–77.
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., and
Sodroski, J. (2004). The cytoplasmic body component TRIM5alpha restricts
HIV-1 infection in Old World monkeys. Nature 427, 848–853.
Swartz, T.H., Esposito, A.M., Durham, N.D., Hartmann, B.M., and Chen, B.K.
(2014). P2X-selective purinergic antagonists are strong inhibitors of HIV-1
fusion during both cell-to-cell and cell-free infection. J. Virol. 88, 11504–11515.
Tartour, K., Appourchaux, R., Gaillard, J., Nguyen, X.N., Durand, S., Turpin, J.,
Beaumont, E., Roch, E., Berger, G., Mahieux, R., et al. (2014). IFITM proteins
are incorporated onto HIV-1 virion particles and negatively imprint their infec-
tivity. Retrovirology 11, 103.
Van Damme, N., Goff, D., Katsura, C., Jorgenson, R.L., Mitchell, R., Johnson,
M.C., Stephens, E.B., and Guatelli, J. (2008). The interferon-induced protein
BST-2 restricts HIV-1 release and is downregulated from the cell surface by
the viral Vpu protein. Cell Host Microbe 3, 245–252.
Weidner, J.M., Jiang, D., Pan, X.B., Chang, J., Block, T.M., and Guo, J.T.
(2010). Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit
vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84, 12646–
12657.
Wen, X., Ding, L., Wang, J.J., Qi, M., Hammonds, J., Chu, H., Chen, X., Hunter,
E., and Spearman, P. (2014). ROCK1 and LIM kinase modulate retrovirus
particle release and cell-cell transmission events. J. Virol. 88, 6906–6921.
Yount, J.S., Karssemeijer, R.A., and Hang, H.C. (2012). S-palmitoylation
and ubiquitination differentially regulate interferon-induced transmembrane
protein 3 (IFITM3)-mediated resistance to influenza virus. J. Biol. Chem. 287,
19631–19641.
Zhao, X., Guo, F., Liu, F., Cuconati, A., Chang, J., Block, T.M., and Guo, J.T.
(2014). Interferon induction of IFITM proteins promotes infection by human
coronavirus OC43. Proc. Natl. Acad. Sci. USA 111, 6756–6761.
Zhong, P., Agosto, L.M., Munro, J.B., and Mothes, W. (2013). Cell-to-cell
transmission of viruses. Curr. Opin. Virol. 3, 44–50.
Zhu, X., He, Z., Yuan, J., Wen, W., Huang, X., Hu, Y., Lin, C., Pan, J., Li, R.,
Deng, H., et al. (2015). IFITM3-containing exosome as a novel mediator for
anti-viral response in dengue virus infection. Cell. Microbiol. 17, 105–118.
